Neuphoria Therapeutics (NEUP) Non-Current Assets (2021 - 2026)

Neuphoria Therapeutics (NEUP) has reported Non-Current Assets for 6 consecutive years, with $13.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 3.46% year-over-year to $13.2 million in Q1 2026; TTM through Mar 2026 was $53.3 million, a 5.38% decrease from a year earlier, with the FY2025 full-year figure at $13.5 million, down 6.27% from the prior year.
• Non-Current Assets was $13.2 million for Q1 2026 at Neuphoria Therapeutics, roughly flat from $13.2 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $16.8 million in Q2 2022 and troughed at $13.2 million in Q1 2026.
• A 5-year average of $14.2 million and a median of $13.7 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets slipped 9.04% in 2023 and dropped 3.46% in 2026, its largest moves.
• Over 5 years, Non-Current Assets stood at $16.8 million in 2022, then retreated by 9.04% to $15.3 million in 2023, then decreased by 10.07% to $13.8 million in 2024, then declined by 4.05% to $13.2 million in 2025, then decreased by 0.45% to $13.2 million in 2026.
• The last three Non-Current Assets figures came in at $13.2 million (Q1 2026), $13.2 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.